A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients

Trial Profile

A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 16 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 10 Jan 2008 Status changed from in progress to completed.
    • 26 Jun 2007 Status changed from recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top